Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Data on vaccines described by J.H. Mcarthur et al
December 31st, 2008
According to a study from the United States, "The rDEN4A/30-200,201 is a live attenuated DENV-4 vaccine candidate specifically designed to further attenuate the rDEN4 Delta 30 parent virus. In the present study, 28 healthy adult volunteers were randomized to receive either 105 plaque-forming unit (PFU) of vaccine (20) or placebo (8) as a single subcutaneous injection." "Volunteers were evaluated for safety every other day for 16 days. Serum neutralizing antibody titer against DEN4 was determined at study day 28, 42, and 180. The vaccine infected all vaccinees and was well tolerated without inducing alanine aminotransferase (ALT) elevations. Although virus was not...
Source: Vaccine Weekly (2008-12-31)
|
